Dear investors and analysts,

We’ve had a very productive quarter and hope this addendum will serve as a tool to highlight ESG activity including updates that were published during Q3.

This quarter we are spotlighting all things Environment including an update on our plan for nature, our plans for nature-related financial disclosures and our partnership to develop a toolkit of practical guidance to support those working on nature-based solutions.

As with last quarter, we love to hear from you so please reach out to our team with your comments and questions.

Thank you,

GSK Investor Relations
irteam@gsk.com

Six areas of focus
We are guided by our purpose to unite science, technology, and talent to get ahead of disease together. Integral to this is running a responsible business, one which builds trust and reduces risk to deliver sustainable health impact at scale, shareholder returns, and to support our people to thrive. To do so, we have prioritised our resources to focus on six material areas:
ESG highlights from our Q3 2023 results presentation

Global health and health security
• New research published in Science showed that a naturally occurring bacterium discovered by GSK scientists could be the basis for new anti-malarial interventions

Environment
• Published updated plan for nature in line with the goal of the Global Biodiversity Framework to halt and reverse biodiversity loss by 2030

Diversity, equity and inclusion
• Launched new, multi-year fund focused on advancing community engagement for gender equality in Africa
Spotlight: Environment

September was a busy month for environmental updates, especially with the hotbed of activity at NY Climate Week. Here are some of the GSK updates you may have missed:

- We published an update on our plan for nature, building on our targets set in 2020, in line with the goal of the Global Biodiversity Framework to halt and reverse biodiversity loss by 2030. The plan includes action across freshwater, land, oceans and atmosphere, the major components of the natural world and home to the biodiversity of the planet’s living species.

- The Task Force on Nature-related Financial Disclosures (TNFD) published its final framework – an outcome of the pilot framework GSK and others were already testing. In alignment with this, we announced a commitment to adopting TNFD-aligned disclosures in 2026, based on 2025 data.

- In partnership with Pollination, and with input from leading environmental and health experts, we published an innovative toolkit providing practical guidance to support those working on nature-based solutions to help ensure that human health is a central outcome of global efforts to protect and restore nature. Pollination will be working with project developers and investors to pilot and further develop the toolkit, and we are sharing it publicly, so that it can be more widely used. More information on this work can be found here.
Recent questions from investors

1. **What are your net zero commitments and related timelines?**

   We set a clear pathway to Net Zero impact on climate.

   By 2030, we will reduce carbon emissions by 80% with remaining 20% offset through investment in high-quality nature-based solutions.

   By 2045, we will be at the Science Based Targets initiative’s standard for Net Zero, with carbon emissions reduced by at least 90% and remaining 10% tackled through high-quality offsets.

2. **What is your view on offsetting emissions?**

   Our priority is decarbonisation.

   We have committed to 90% emissions reduction by 2045 and intend to use high-quality carbon credit only for 10% residual emissions left in 2045.

   Our approach is to invest in early-stage nature projects to ensure credits we use for our net zero strategy are from high quality projects that we have been involved in from the beginning and have been chosen because they provide benefit to climate, nature and local communities.

   Our first large scale nature restoration project is an ambitious 2,500 hectares mangrove restoration in Indonesia. This will deliver benefits for climate, nature and local communities.

3. **What is the latest on low-carbon Ventolin?**

   We are fully committed to reducing our global carbon emissions, of which approximately half are generated by our MDI, Ventolin - a medicine that 35m patients around the world rely on as their rescue medication to relieve shortness of breath in asthma and COPD.

   A new, lower carbon, formulation of Ventolin is now in clinical trials and, if development is successful, it has the potential to reduce the carbon footprint from this important medicine by approximately 90%.

   We have already started the work to bring this important new medicine to patients as soon as possible.
Committed to ESG investor engagement

While we are always open to discussing ESG topics with the investment community over email and through meeting requests, we also block time during the year dedicated to ESG investor engagement.

Our next ESG investor focused days are:

- 7 November 2023: Société Générale ESG Conférence, Paris, France

If you are interested in meeting with us during these events or the next time we are planning ESG investor engagement days, please reach out to our team.

Featured speakers

- **Clare Griffin**
  *Vice President of Reputation and Responsible Business*

- **Claire Lund**
  *Vice President for Environmental Sustainability*

- **Frannie DeFranco**
  *Director of Investor Relations*